Breaking News

Allergan May Opt to Acquire LTI in Parkinson’s Pact

Decision to follow completion of Phase Ib trial for LTI-291

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan has purchased an exclusive option right to acquire Lysosomal Therapeutics (LTI), a drug developer focused on small-molecule R&D in the field of neurodegeneration.   LTI’s lead program, LTI-291, aims to stimulate the activity of glucocerebrosidase (GCase) in the brain. In several lysosomal storage diseases, the activity of GCase is reduced due to genetic mutations in the GBA1 gene. Approximately 5 to 10 percent of patients with Parkinson’s disease (PD) have mutations of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters